Dear Doctor Letter (Rote-Hand-Brief) on Pradaxa® (dabigatran etexilate): New contraindication
2013.01.09
Active substance: dabigatran etexilate
The pharmaceutical manufacturer is sending out information that the medicinal product Pradaxa® is now contraindicated in patients with artificial heart valves who require anticoagulant treatment.
Please also notice the former publications at our homepage:
Rote-Hand-Brief from 2011.10.27
Press release on Pradaxa® from 2011.11.16
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN